Abstract:
PURPOSE: A pharmaceutical composition containing hematein which is obtainable by extraction of Heartwood of Caesalpinia sappan or commercially as an active ingredient is provided. Because the hematein exhibits LDL-antioxidant activity, remarkably reduces cholesterol in blood and strongly inhibits liver microsome ACAT activity, the composition can be effectively used in prevention and therapeutic treatment of atherosclerosis and hyperlipidemia. CONSTITUTION: The composition for preventing and treating atherosclerosis and hyperlipidemia in mammals contains an effective amount of hematein and a pharmaceutically acceptable carrier as an active component. The hematein inhibits the activity of acyl-CoA : cholesterol acyltransferase or acts as LDL-antioxidant to give an effect on preventing and treating hyperlipidemia.
Abstract:
PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
Abstract:
PURPOSE: A pharmaceutical composition and functional food and drink comprising tannin or phenol-type compounds derived from tannin are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises tannin, gallic acid, ellagic acid or their mixture in effective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of tannin, gallic acid, ellagic acid or their mixture. Tannin, gallic acid and ellagic acid reduce the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase), gamma GTP (gamma-glutamyl transpeptidase) and a lipid in blood, and inhibit the damage of a liver cell and the formation of a fatty liver. Also tannin, gallic acid and ellagic acid strongly inhibit the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.
Abstract:
PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract:
PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract:
본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
PURPOSE: Food composites including tannin or tannin-derived phenolics are provided to prevent and treat arteriosclerosis, hyperlipidemia and hepatic steatosis by dosing tannin, gallic acid or/and ellagic acid. CONSTITUTION: Tannin, gallic acid or/and ellagic acid is/are added to a food or a drink to prevent and treat arteriosclerosis. Tannin(C76H52O46) is extracted from acorns, persimmons and walnut shells. Gallic acid(C7H6O5) and ellagic acid(C14H6O8) are the decomposition products of tannin and have anticancer activities. The amount of the tannin-derived phenolics is from 0.01wt.% to 20wt.% according to the weight, age, gender, health status, diet, dosage time and method, excretory rate and disease level of patients.
Abstract:
PURPOSE: A composition containing tannin, gallic acid or ellagic acid is provided for preventing and treating arteriosclerosis, hyperlipemia and liver diseases. CONSTITUTION: When tannin, gallic acid or ellagic acid are administrated into an animal body, they prevent the deposition of macrophage-lipid complex within the inner surface of arterial duct, decrease the concentration of GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase), gammaGTP(gamma-glutamyl transpeptidase), and lipid in serum, and strongly inhibit the damage of liver cells and the progress of fatty liver. The composition contains an effective of ellagic acid displaying an anticancer activity, that is 0.1 mg to 500 mg/weight kg a day. The composition is preferably administrated into an animal body 5 times a day in a dosage of 1 mg to 100 mg/weight kg.
Abstract:
PURPOSE: A pharmaceutical composition containing one of rutin and Quercetin or the mixture is provided to prevent and treat hyperlipidemia, arteriosclerosis and liver diseases. CONSTITUTION: The rutin is extracted from buckwheat or leaves, stems and flowers of the buckwheat by leaving the materials at a base of pH10-12 by using calcium hydroxide, neutralizing and settling the materials, or by using 20-97% alcohol or water at a high temperature and pressure. The buckwheat and the leaves, stems and flowers also can be dried and pulverized to get powdered buckwheat. The resulting buckwheat flour or buckwheat extract containing 0.01-10wt% of the rutin, quercetin or the mixture of them is added to tomato ketchup, sauce and juice, ramen, noodle, bread, cookies and cracker, soup and gravies, ground beef, or dairy products to get functional foods.